Prognosis for early-stage cancer is primarily based on tumor type, disease burden, and aggressiveness suggested by clinical, imaging, laboratory, pathologic, and molecular characteristics. For more advanced cancers, functional status has consistently demonstrated an association with survival, although length...
Thus, we developed an objective scoring system to evaluate reliably CD44v6 (Bender Medsystems, Vienna, Austria) as a prognostic marker for prostate cancer. A total of 22 patients with metastatic stage pT3bN0M0 or any pTN1M0 disease and 18 with nonmetastatic disease less than stage pT3bN0M0...
In our models, we included and controlled for the clinical covariates age at diagnosis, gender, and tumor stage. For comparison, we also built standard Cox regression models based on the clinical covariates alone. We evaluated the predictive performance of our models using Harrell’s concordance ...
Results: For patients with colorectal cancer, cutaneous melanoma or stage I breast cancer, conditional 5-year relative survival was >95% after having survived 3-15 years. However, for stomach, lung, stage II or III breast, prostate cancer or Hodgkin lymphoma, conditional 5-year relative ...
THE IMPACT OF PROGNOSIS ON THE TREATMENT OF EARLY STAGE PROSTATE CANCER PATIENTSDavid H Howard, PhD
For most men, prostate cancer is slow-growing, does not lead to clinical signs in the early stage and is usually detected by routine testing5. However, in some men, PCa progresses quickly and can cause hematuria or urinary obstruction. Cancer that spreads past the gland may result in lower...
An investigation of the relationship between blood type and prostate cancer stage, grade and prognosisPurpose: To determine prevalence and patterns of use of complementary and alternative medicine (CAM) among men recently diagnosed with prostate cancer. Study Design: Men, diagnosed with prostate cancer...
Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED. Presented at: ASCO Annual Meeting; 2019; Chicago, IL. 14. Cerami E, Gao J, Dogrusoz U, et al. The ...
Risk categories based on prostate-specific antigen (PSA), Gleason score, and Clinical Stage that predict PSA failure [1], underpin the treatment of localized prostate cancer, as illustrated, for example, by the UK National Institute for Health and Care Excellence guidelines [2]. Attempts to impr...
Reliable prognostic biomarkers to distinguish indolent from aggressive prostate cancer (PCa) are lacking. Many studies investigated microRNAs (miRs) as PCa prognostic biomarkers, often reporting inconsistent findings. We present a systematic review of th